Alopecia areata. Pathogenesis and rational treatment of a T-cell mediated autoimmune disease

被引:8
作者
Freyschmidt-Paul, P [1 ]
Happle, R [1 ]
Hoffmann, R [1 ]
机构
[1] Univ Marburg, Klin Dermatol & Allergol, D-35033 Marburg, Germany
来源
HAUTARZT | 2003年 / 54卷 / 08期
关键词
alopecia areata; T-cells; apoptosis; autoimmune disease; contact dermatitis;
D O I
10.1007/s00105-003-0560-z
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Alopecia areata is a T-cell mediated autoimmune disease directed against an unknown auto antigen of the hair follicle. There is a genetic predisposition to develop alopecia areata, whereas environmental triggers have so far not been identified. The diagnosis can be established by characteristic clinical features of alopecia areata including its severe forms alopecia areata totalis and universalis. Nail changes may help confirm the diagnosis. On rare occasions a histopathological examination may be necessary, whereas other laboratory investigations are unnecessary. Because of the high rate of simultaneous remission, the efficacy of a rational treatment of alopecia areata has to be proven in controlled studies and it should be associated with only minor side effects. According to the rules of evidence-based medicine, treatment with a contact sensitizer is at present the most effective treatment of alopecia areata showing only mild side effects. However, it is time-consuming and in some cases ineffective, making it desirable to develop new, more specific forms of treatment.
引用
收藏
页码:713 / 722
页数:10
相关论文
共 46 条
[1]   Role of cytotoxic T cells in chronic alopecia areata [J].
Bodemer, C ;
Peuchmaur, M ;
Fraitaig, S ;
Chatenoud, L ;
Brousse, N ;
de Prost, Y .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (01) :112-116
[2]   ABNORMAL EXPRESSION OF CLASS-I AND CLASS-II MAJOR HISTOCOMPATIBILITY ANTIGENS IN ALOPECIA-AREATA - MODULATION BY TOPICAL IMMUNOTHERAPY [J].
BROCKER, EB ;
ECHTERNACHTHAPPLE, K ;
HAMM, H ;
HAPPLE, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1987, 88 (05) :564-568
[3]   Randomized double blind placebo-controlled trial in the treatment at alopecia areata with 0.25% desoximetasone cream [J].
Charuwichitratana, S ;
Wattanakrai, P ;
Tanrattanakorn, S .
ARCHIVES OF DERMATOLOGY, 2000, 136 (10) :1276-1277
[4]  
Cork M J, 1995, J Invest Dermatol, V104, p15S
[5]   ALOPECIA-AREATA - A CLINICAL-STUDY [J].
DEWEERT, J ;
TEMMERMAN, L ;
KINT, A .
DERMATOLOGICA, 1984, 168 (05) :224-229
[6]   Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T-cell receptor-repertoire among infiltrating lymphocytes [J].
Dressel, D ;
Brutt, CH ;
Manfras, B ;
Zollner, TM ;
Wunderlich, A ;
Bohm, BO ;
Boehncke, WH .
JOURNAL OF CUTANEOUS PATHOLOGY, 1997, 24 (03) :164-168
[7]   Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice [J].
Freyschmidt-Paul, P ;
Sundberg, JP ;
Happle, R ;
McElwee, KJ ;
Metz, S ;
Boggess, D ;
Hoffmann, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (01) :61-68
[8]   Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice [J].
Freyschmidt-Paul, P ;
Seiter, S ;
Zöller, M ;
König, A ;
Ziegler, A ;
Sundberg, JP ;
Happle, R ;
Hoffmann, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (04) :653-657
[9]   Interleukin-10-deficient mice are less susceptible to the induction of alopecia areata [J].
Freyschmidt-Paul, P ;
McElwee, KJ ;
Happle, R ;
Kissling, S ;
Wenzel, E ;
Sundberg, JP ;
Zöller, M ;
Hoffmann, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (04) :980-982
[10]  
Freyschmidt-Paul P, 2001, EUR J DERMATOL, V11, P405